Bethany Pellegrino, MD

Professor and Nephrology Division Chief
Nephrology Fellowship Program Director

Organization:

West Virginia University School of Medicine

Department:

Medicine

Classification:

Faculty

• MD, WVU School of Medicine

Publications

Schmidt RJ, Pellegrino B, MacKay K, Parravani A, Mustafa R, and Hobbs G.“Prevalence and Predictive Value of Hypoalbuminemia in Appalachians with Chronic Kidney Disease.”  World J Nephrol Urol. 2012; 1(1):  8-15.

Schmidt RJ and Pellegrino B, Guest Editors.  Primary Care of the Patient with Chronic Kidney Disease.   Adv Chronic Kidney Dis. 18:6, 2011.

Pellegrino B and Schmidt RJ.  “Why Work Together? Developing Effective Comanagment Strategies for the Care of Patients with CKD.”  Adv Chronic Kidney Dis. November 2011. 18 (6): 396-399.

Schmidt RJ and Pellegrino B. “Collegiality and CKD.” Adv Chronic Kidney Dis, November 2011. 18 (6): 394-395.

Moss A, Ganjoo J, Sharma S, Gansor J, Senft S, Weaner B, Dalton C, Mackay K, Pellegrino B, Anantharaman P, Schmidt R.  “Utility of the Surprise Question to Identify Dialysis Patients with High Mortality.” Clin J Am Soc Nephrol. 2008 Sep 3(5): 1379-84.

Pellegrino B, Paravanni A, Cook L, Mackay KM.  “Ethylene Glycol Intoxication:  Disparate Findings of Immediate versus Delayed Presentation.” West Virginia Medical Journal.  July/August 2006. 102(4): 32-34.

Pellegrino B and Schmidt RJ (November 17, 2011, revised) Immunosuppression. Retrieved from: Emedicine.medscape.com/article/432316-overview

Awards

2016:            Cornerstone of Recovery Award

2015:            Press Ganey Top Provider Award: Patient Satisfaction

2014:            Press Ganey Top Provider Award, Patient Satisfaction

2012:            Press Ganey Top Provider Award, Patient Satisfaction

2004:            Margaret J. Albrink, MD Research Award; WVU Department of Medicine

2000:            American Society of Nephrology Annual Meeting, Toronto Resident Program

2000:            Teaching Intern of the Year Award Nomination

1999:            West Virginia University Medical Scholarship Award

Professional Organizations

1999-2017:  American College of Physicians- Fellow

1999-2017:  American Medical Association

1995-2006:  West Virginia State Medical Association

2002-2017:  National Kidney Foundation

2002-2017:  American Society of Nephrology- Fellow

2012-2017:  Women in Nephrology

2005-2012:  International Society of Nephrology

2005-2017:  Renal Physicians Association

2007-2017:  International Society for Peritoneal Dialysis

Dr. Bethany Pellegrino is currently a Professor of Medicine in the Division of Nephrology in the Department of Medicine. She graduated from West Virginia University School of Medicine and completed her residency in Internal Medicine at WVU. She completed her fellowship in Nephrology also at WVU, joining the faculty in the Division of Nephrology in 2004.  She served as Nephrology Fellowship Program Director from 2012-2016. She is currently Medical Director of the Renal Center of Keyser (WV) and the Renal Center of Moorefield (WV). Dr. Pellegrino's interests include home dialysis therapies and improving access for patients with kidney disease throughout West Virginia. She is a Fellow of the American College of Physicians and a Fellow of the American Society of Nephrology.

Research

2016-present:  Optimizing the Outcomes of PD Catheter Insertion.  International Society of Peritoneal Dialysis-NA Chapter.  Primary Investigator.

2016-present: A Phase 3, prospective, multicenter, double-blind, randomized, active control study to demonstrate the safety and effectiveness of Neutrolin in preventing catheter-related bloodstream infections in subjects receiving hemodialysis therapy as treatment for end stage renal disease.  (CorMedix protocol LOCK-IT-100) Co-Investigator

2015-present:   Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis. FibroGen Protocol FGCL-4592-060.  Co-Investigator

2015: Dialysis Outcomes and Practice Patterns Study, 2012-2015 (DOPPS 5).  Primary Investigator

2015-present:  Alexion Pharmaceuticals Protocol M11-001: An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients with Atypical Hemolytic-Uremic Syndrome (AHUS Registry). Sub-Investigator

2014-present: Utility of an Integrated Diagnostic Tool for Outcomes in Patients with Stages 4 and 5 Chronic Kidney Disease.  Co-Investigator

2014-present: Chronic Kidney Disease Outcomes and Practice Patterns Study. (CKDOPPS). Co-Investigator

2014-present: A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease. Sub-Investigator

2014: Protocol M11-352  (SONAR):  Randomized, Multicenter, Multi country, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan.  ABBVie Pharma.  Co-Investigator

2011:  Vifor (International) Inc: An Open-label, Randomized, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared with Sevelamer Carbonate Followed by a Randomized Comparison of PA21-Maintenance Dose Versus PA21-Low Dose in Dialysis Patients with Hyperphosphataemia.  Sub-Investigator

2011:  Shire Pharmaceuticals: Burden of AV GRaft and FIstula Complications in chronic kidney disease patients (GRAFIC).  Sub-Investigator

2011:  Reata Pharmaceuticals: Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON).  Co-Investigator.

2010-2011:  Randomized Evaluation of Efficacy and Safety of Ferric Carboxymaltose in Patients with Iron Deficiency Anemia and Impaired Renal Function.  (Luitpold-REPAIR-IDA STUDY).  Co-Investigator

2010:  Dialysis Outcomes and Practice Patterns Study (DOPPS 4).    Principal Investigator

2010:  A Predictive Model for Chronic Kidney Disease (CKD) Outcomes.   Co-Investigator

2010:  Chronic Kidney Disease Outcomes in Rural West Virginia Clinics.  Co-Investigator

2007-2013:   Amgen Protocol 20050182:  Evaluation of Cinacalcet HCL Therapy to Lower CardioVascular Events (EVOLVE), Principal Investigator2008:  A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Fixed Dose Study of AMG 223 in Subjects with Chronic Kidney Disease on Hemodialysis with Hyperphosphatemia, Principal Investigator

2007-2009:  Dialysis Outcomes and Practice Patterns Study (DOPPS 3), Principal Investigator

2006:   Secondary Hyperparathyroidism and Autonomic Dysfunction in Early Chronic Kidney Disease, Principal Investigator.

2005-2007:  Dialysis Outcomes and Practice Patterns Study (DOPPS 2), Principal Investigator

2005:    Open Label Extension Study Evaluating the Long Term Safety, Tolerability and    Efficacy of an Iron Maintenance Dosing Study Utilizing Intravenous VIT-45 in the Treatment of Anemia in Non-Dialysis Dependant CKD (1VIT05005), Co-Primary Investigator

2005:    Comparison of the Safety and Efficacy of a Unique Intravenous Iron Preparation (VIT-45) versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease (1VIT04004), Co-Primary Investigator

2005:    A Randomized, Open-Label Study to Assess the Safety of Epoetin Alfa Manufactured by Deep Tank Technology and Epoetin Alfa Manufactured by Roller Bottle Technology in Subjects with CKD.  (20040259) Sub-investigator

2002:  Renal Biopsy Database. Principal Investigator

Medical Specialties

• Nephrology/Kidney Disease

Board Certifications

• Internal Medicine, American Board of Internal Medicine
• Nephrology, American Board of Internal Medicine

Special Training

• Residency, Internal Medicine
  WVU Department of Medicine
• Fellowship, Nephrology
  WVU Department of Medicine